Keytruda (pembrolizumab)

pCPA File Number: 21139
Negotiation Status:
Negotiations were not pursued
Indication(s):
Metastatic Urothelial Carcinoma (first line)
Sponsor/Manufacturer:
Merck Canada Inc.
CDA-AMC Project Number:
PC0177-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: